Ants could be the next line of defense against cancer.

A study published in the journal Proceedings of Royal Society B: Biological Sciences focused on Ants and their keen sense of smell. Ants use smell via their thin sensory appendages that sit on top of their heads to do almost everything, including hunt for food, spotting mates, and protecting their young.

In the study, scientists used pieces of a breast cancer tumor, which were grafted onto mice, and then trained 35 ants to associate urine from the infected mice with sugar. In analyzing, scientists detected that the ants would hover for longer periods of time near the sick mouse rather than the healthy one.

Using ants to detect cancers would be a cost-cutting tool. Currently, cancers are diagnosed by blood withdrawal, biopsies, and colonoscopies, which are all considered invasive as well as being expensive procedures. Utilizing ants to screen for cancer would be significantly more reasonable.

While dogs have similar capabilities in that they are able to detect cancer in humans through smell, they take much longer to train. Baptiste Piqueret, a postdoctoral fellow at the Max Planck Institute for Chemical Ecology in Germany, said ants would be the ideal animal to use because they have good memories, are easy to train and don't bite.

Though progress has been made with ants and their cancer detection capabilities, there is still more research to be done on their efficacy. The next phase of the study will be human trials to see if ants are able to sniff out cancers through human excrement.

Share:
More In Science
As U.S. Opioid Crisis Worsens, Price of Life-Saving Drug Naloxone Skyrockets
Jill Wagner and Baker Machado break down the state of the Opioid Crisis in the U.S. The CDC reported a 30% increase in overdose deaths from 2020 to 2021, but in recent months pharmaceutical companies have drastically raised the price of Naloxone or 'Narcan,' affecting the response of community harm prevention groups.
Regeneron Joins Battle Against COVID-19, Releases Stats on New COVID Treatment
The world hit a grim milestone on Monday, with COVID-19 cases surpassing a quarter of a billion worldwide. As cases increase, the fight to beat the virus continues as well, with a number of medical breakthroughs coming out over the last few months in the form of pills from Pfizer and Merck. Regeneron is now the latest company to join the fight, recently releasing new data on a covid antibody cocktail. Professor Peter Pitts, former FDA Associate Commissioner and the founder of the Center for Medicine in the Public Interest breaks down the differences between the 3 treatments and why vaccines are still among the fire line of defense.
Legal Questions Swirl as States Push Back Against Biden COVID Vaccine Mandate
The Biden Administration's mandate for COVID vaccinations by large employers has been put on hold by federal courts as GOP-led states and some businesses push back on the order's legality. Jonathan Adler, a law professor at Case Western Reserve University, joined Cheddar to discuss the legal challenges to implementing such mandates through OSHA (Occupational Safety and Health Administration). "Certainly expanding vaccinations is a good thing, and as vaccination rates go up that's better for all of us," Adler said. "But there are some legal questions about whether or not it's appropriate to use a law about occupational safety and health as the means to do that."
What COVID-19 Vaccines for Kids Might Mean for Fight Against Pandemic
Dr. Robert Frenck, an infectious disease specialist at Cincinnati Children's Hospital, joined Cheddar to talk about the significance of children ages 5-11 being authorized to receive COVID-19 vaccinations. He also discussed schools being cleared to administer vaccines and noted the importance of meeting people where they are rather than forcing them to find the shots. Frenck also said he expects that children under 5 years old will begin getting vaccinations sometime in spring.
Everything You Need to Know About Child Covid-19 Vaccines
A CDC advisory committee as unanimously voted to recommend the Pfizer Covid-19 vaccine in children ages 5 to 11. Dr. Amesh Adalja, Infectious Disease Specialist and Senior Scholar at Johns Hopkins Center for Health Security, joined Cheddar News to discuss.
Load More